Cogent Biosciences Inc

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

COGT$31.64-5.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Operating expenses:
Research and development	$54,294	$38,871	$106,999	$74,909
General and administrative	10,093	8,214	19,792	15,413
Total operating expenses	64,387	47,085	126,791	90,322
Loss from operations	(64,387)	(47,085)	(126,791)	(90,322)
Other income:
Interest income	5,393	2,741	9,450	5,009
Other income, net	44	268	43	950
Change in fair value of CVR liability	—	—	—	1,700
Total other income, net	5,437	3,009	9,493	7,659
Net loss	$(58,950)	$(44,076)	$(117,298)	$(82,663)
Net loss per share attributable to common stockholders, basic and diluted	$(0.59)	$(0.59)	$(1.21)	$(1.14)
Weighted average common shares outstanding, basic and diluted	99,240,030	74,753,269	97,022,345	72,755,210
Comprehensive loss:
Net loss	$(58,950)	$(44,076)	$(117,298)	$(82,663)
Other comprehensive loss:
Net unrealized gains (losses) on marketable securities	(153)	(113)	(438)	7
Total other comprehensive loss	(153)	(113)	(438)	7
Comprehensive loss	$(59,103)	$(44,189)	$(117,736)	$(82,656)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.